ProKidney Corp. (PROK)

NASDAQ: PROK · Real-Time Price · USD

2.330

-0.040 (-1.69%)

At close: Sep 6, 2024, 4:00 PM

2.410

+0.080 (3.43%)

After-hours: Sep 6, 2024, 7:50 PM EDT

ProKidney Employees

ProKidney had 163 employees as of December 31, 2023. The number of employees increased by 76 or 87.36% compared to the previous year.

Employees

163

Change (1Y)

76

Growth (1Y)

87.36%

Revenue / Employee

n/a

Profits / Employee

-$237,319

Market Cap

293.70M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	163	76	87.36%
Dec 31, 2022	87	28	47.46%
Dec 31, 2021	59	-	-

Related Stocks

Company Name	Employees
Aurora Cannabis	1,073
AngioDynamics	748
Spok Holdings	384
Editas Medicine	265
Vanda Pharmaceuticals	203
AC Immune	161
TScan Therapeutics	154
Sanara MedTech	108

Employee Rankings

PROK News

5 days ago - ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. - GlobeNewsWire
12 days ago - ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire
4 weeks ago - ProKidney Reports Business Updates and Second Quarter 2024 Financial Results - GlobeNewsWire
3 months ago - ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering - GlobeNewsWire
3 months ago - ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering - GlobeNewsWire
3 months ago - ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates - GlobeNewsWire
3 months ago - ProKidney to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
3 months ago - ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024 - GlobeNewsWire